Table 4. Differences in clinical characteristics between pemetrexed + S-1 + bevacizumab and other regimens.

Analyzing factors	Pem + S-1 + Bev	Other regimens	t/c2	P
Number of patients	21	67	–	–
Gender, n (%)			0.939	0.333
Male	11 (52.38)	43 (64.18)
Female	10 (47.62)	24 (35.82)
Average age	61.24±9.23	59.57±10.81	0.639	0.525
Disease process, n (%)			0.221	0.638
Initial diagnosis stage IV	10 (47.62)	28 (41.79)
Relapse stage IV	11 (52.38)	39 (58.21)
Metastasis site, n (%)
Abdominal cavity	4 (19.05)	6 (8.96)	0.77	0.38
Liver	11 (52.38)	47 (70.15)	2.247	0.134
Lung	3 (14.29)	38 (56.72)	11.568	0.001*
Lymph nodes	6 (28.57)	16 (23.88)	0.188	0.665
Other	5 (23.81)	12 (17.91)	0.079	0.779
Primary tumor location, n (%)			0.013	0.911
Left colon	15 (71.43)	47 (70.15)
Right colon	6 (28.57)	20 (29.85)
RAS, BRAF gene mutation, n (%)			–	0.002*
All wild type	5 (23.81)	11 (16.42)
Unknown	6 (28.57)	46 (68.66)
KRAS	9 (42.86)	10 (14.93)
BRAF	1 (4.76)	0 (0)
Targeted drug use in previous therapies, n (%)
Unused	3 (14.29)	39 (58.21)	12.364	<0.001*
Bevacizumab	14 (66.67)	20 (29.85)	9.141	0.002*
Cetuximab	2 (9.52)	7 (10.45)	0	>0.999
Other regimens	2 (9.52)	1 (1.49)	–	0.14

*, P<0.05. Pem, Pemetrexed; Bev, Bevacizumab.